Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Lung 3 in first-line squamous NSCLC
NL-OMON39315Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nintedanib in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities and Progression-free survival. Started Mar 2012; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON39315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39315.